3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
555
Triple Negative Breast Neoplasms
94
Inflammatory Breast Neoplasms
38
Breast Neoplasms, Male
31
Neoplasm Metastasis
27
Ovarian Neoplasms
25
Carcinoma, Non-Small-Cell Lung
23
Melanoma
21
Pancreatic Neoplasms
14
Neoplasms
14
Colorectal Neoplasms
13
Carcinoma, Renal Cell
12
Stomach Neoplasms
11
Multiple Myeloma
10
Lung Neoplasms
10
Carcinoma, Ovarian Epithelial
9
Carcinoma, Hepatocellular
9
Lymphoma, Non-Hodgkin
8
Sarcoma
7
Lymphoma, Follicular
7
Lymphoma
7
Carcinoma, Ductal, Breast
7
Recurrence
6
Neutropenia
6
Lymphoma, Mantle-Cell
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myeloid, Acute
6
Leukemia, Lymphocytic, Chronic, B-Cell
6
Interventions
Fulvestrant
19
Letrozole
10
Anastrozole
8
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Injections
4
Goserelin
4
Docetaxel
4
trastuzumab deruxtecan
3
pyrotinib
3
exemestane
3
Vinorelbine
3
Aromatase Inhibitors
3
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
dalpiciclib
2
abemaciclib
2
Trastuzumab
2
Gonadotropin-Releasing Hormone
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
Cyclophosphamide
×
Breast
×
Clear all
NCT04304352
2023-06-28
VEX
European Institute of Oncology
Phase 2
Unknown
162 enrolled